News | February 23, 2022
Vicore advances on new chemical entity from VP03 program
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
John served as General Manager for Catalent Pharma Solutions in St. Petersburg, Florida
Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
US $ 555,000 invested by Wavemaker Partners in pre-seed round
Subscribe To Our Newsletter & Stay Updated
